Qian Ye

Qian Ye

Auto-generated profile, based on publicly available information

Qian Ye

Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
QYQian Ye
Qian Ye
YLYi Liu
Yi Liu
GZGuiji Zhang
Guiji Zhang
HDHaijun Deng
Haijun Deng
XWXiaojun Wang
Xiaojun Wang
NTNi Tang
Ni Tang
Metabolic associated fatty liver disease (MAFLD) encompasses a broad spectrum of hepatic disorders, including steatosis, nonalcoholic steatohepatitis (NASH) and fibrosis. We demonstrated that phosphoenolpyruvate carboxykinase 1 (PCK1) plays a central role in MAFLD progression. Male mice with liver Pck1 deficiency fed a normal diet displayed hepatic lipid disorder and liver injury, whereas fibrosis and inflammation were aggravated in mice fed a high-fat diet with drinking water containing fructose and glucose (HFCD-HF/G). Forced expression of hepatic PCK1 by adeno-associated virus ameliorated MAFLD in male mice. PCK1 deficiency stimulated lipogenic gene expression and lipid synthesis. Moreover, loss of hepatic PCK1 activated the RhoA/PI3K/AKT pathway by increasing intracellular GTP levels, increasing secretion of platelet-derived growth factor-AA (PDGF-AA), and promoting hepatic stellate cell activation. Treatment with RhoA and AKT inhibitors or gene silencing of RhoA or AKT1 alleviated MAFLD progression in vivo. Hepatic PCK1 deficiency may be important in hepatic steatosis and fibrosis development through paracrine secretion of PDGF-AA in male mice, highlighting a potential therapeutic strategy for MAFLD.

3 December 2025 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
QYQian Ye
Qian Ye
XLXiaofei Lai
Xiaofei Lai
YLYuliang Liu
Yuliang Liu
ZZZhengtao Zhang
Zhengtao Zhang
YFYueqiang Fu
Yueqiang Fu
JCJu Cao
Ju Cao